Malignant priapism - What do we know about it?

5Citations
Citations of this article
18Readers
Mendeley users who have this article in their library.

Abstract

Malignancy as an etiological factor involved in priapism pathogenesis is rare. Malignant priapism (MP) can arise as a result of penile tumor invasion, either from primary penile tumors or from metastatic penile tumors, or due to hematological malignancies. Non-urological penile metastases are associated with significant worse prognosis compared to urological penile metastases, the appearance of priapism in such cases affecting even more the prognosis and the survival of these patients. Patients diagnosed with hematological malignancies and priapism present significant higher survival rates compared to those who develop MP in the context of a non-hematological malignancy, this being related to the fact that hematological malignancies are more sensitive to chemoand radiotherapy. Most malignant priapism cases are ischemic; therefore the management should be based on the initial steps of the IP therapeutic protocol. Considering the trigger factor that has led to the priapic event specific oncologic treatment can be added as well.

Cite

CITATION STYLE

APA

MARCU, D., IORGA, L., MISCHIANU, D., BACALBASA, N., BALESCU, I., & BRATU, O. (2020, September 1). Malignant priapism - What do we know about it? In Vivo. International Institute of Anticancer Research. https://doi.org/10.21873/invivo.12033

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free